![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CYP7A1 |
Gene summary for CYP7A1 |
![]() |
Gene information | Species | Human | Gene symbol | CYP7A1 | Gene ID | 1581 |
Gene name | cytochrome P450 family 7 subfamily A member 1 | |
Gene Alias | CP7A | |
Cytomap | 8q12.1 | |
Gene Type | protein-coding | GO ID | GO:0001678 | UniProtAcc | P22680 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1581 | CYP7A1 | HCC1 | Human | Liver | HCC | 3.64e-12 | 6.88e-01 | 0.5336 |
1581 | CYP7A1 | HCC2 | Human | Liver | HCC | 1.25e-18 | 4.17e+00 | 0.5341 |
1581 | CYP7A1 | Pt13.a | Human | Liver | HCC | 1.41e-03 | 2.08e-01 | 0.021 |
1581 | CYP7A1 | Pt13.b | Human | Liver | HCC | 1.63e-04 | 1.24e-01 | 0.0251 |
1581 | CYP7A1 | Pt14.b | Human | Liver | HCC | 2.87e-02 | 1.39e-01 | 0.018 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
GO:000663122 | Liver | HCC | fatty acid metabolic process | 238/7958 | 390/18723 | 8.24e-14 | 4.84e-12 | 238 |
GO:004639421 | Liver | HCC | carboxylic acid biosynthetic process | 198/7958 | 314/18723 | 1.19e-13 | 6.78e-12 | 198 |
GO:004428221 | Liver | HCC | small molecule catabolic process | 225/7958 | 376/18723 | 6.50e-12 | 2.80e-10 | 225 |
GO:000606621 | Liver | HCC | alcohol metabolic process | 208/7958 | 353/18723 | 2.80e-10 | 9.50e-09 | 208 |
GO:19026522 | Liver | HCC | secondary alcohol metabolic process | 100/7958 | 147/18723 | 3.26e-10 | 1.09e-08 | 100 |
GO:00082032 | Liver | HCC | cholesterol metabolic process | 94/7958 | 137/18723 | 5.39e-10 | 1.72e-08 | 94 |
GO:00082022 | Liver | HCC | steroid metabolic process | 188/7958 | 319/18723 | 1.96e-09 | 5.63e-08 | 188 |
GO:00161252 | Liver | HCC | sterol metabolic process | 101/7958 | 152/18723 | 1.99e-09 | 5.63e-08 | 101 |
GO:006201222 | Liver | HCC | regulation of small molecule metabolic process | 190/7958 | 334/18723 | 6.77e-08 | 1.40e-06 | 190 |
GO:000974322 | Liver | HCC | response to carbohydrate | 149/7958 | 253/18723 | 9.55e-08 | 1.89e-06 | 149 |
GO:007233021 | Liver | HCC | monocarboxylic acid biosynthetic process | 129/7958 | 214/18723 | 1.08e-07 | 2.09e-06 | 129 |
GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
GO:00066951 | Liver | HCC | cholesterol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
GO:19026531 | Liver | HCC | secondary alcohol biosynthetic process | 43/7958 | 57/18723 | 4.37e-07 | 7.23e-06 | 43 |
GO:00161261 | Liver | HCC | sterol biosynthetic process | 47/7958 | 64/18723 | 5.00e-07 | 8.11e-06 | 47 |
GO:003428422 | Liver | HCC | response to monosaccharide | 131/7958 | 225/18723 | 1.32e-06 | 1.91e-05 | 131 |
GO:00066942 | Liver | HCC | steroid biosynthetic process | 104/7958 | 173/18723 | 2.13e-06 | 2.91e-05 | 104 |
GO:004218021 | Liver | HCC | cellular ketone metabolic process | 123/7958 | 211/18723 | 2.52e-06 | 3.37e-05 | 123 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049794 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa033204 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
hsa001202 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
hsa049795 | Liver | HCC | Cholesterol metabolism | 41/4020 | 51/8465 | 1.33e-06 | 1.35e-05 | 7.49e-06 | 41 |
hsa033205 | Liver | HCC | PPAR signaling pathway | 48/4020 | 75/8465 | 2.83e-03 | 9.37e-03 | 5.21e-03 | 48 |
hsa001203 | Liver | HCC | Primary bile acid biosynthesis | 14/4020 | 17/8465 | 3.49e-03 | 1.12e-02 | 6.22e-03 | 14 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYP7A1 | SNV | Missense_Mutation | rs772557610 | c.1145N>A | p.Arg382Gln | p.R382Q | P22680 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-TN-A7HJ-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
CYP7A1 | SNV | Missense_Mutation | c.215N>C | p.Met72Thr | p.M72T | P22680 | protein_coding | tolerated(0.09) | benign(0.242) | TCGA-HC-7750-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
CYP7A1 | SNV | Missense_Mutation | c.1450G>A | p.Ala484Thr | p.A484T | P22680 | protein_coding | deleterious(0.01) | possibly_damaging(0.532) | TCGA-BR-4256-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CYP7A1 | SNV | Missense_Mutation | rs749230759 | c.637N>A | p.Asp213Asn | p.D213N | P22680 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR |
CYP7A1 | SNV | Missense_Mutation | c.183N>T | p.Arg61Ser | p.R61S | P22680 | protein_coding | deleterious(0.01) | benign(0.287) | TCGA-CD-8527-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | epirubicin | PD | |
CYP7A1 | SNV | Missense_Mutation | c.342T>G | p.Ile114Met | p.I114M | P22680 | protein_coding | tolerated(0.34) | benign(0.063) | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CYP7A1 | SNV | Missense_Mutation | c.65N>C | p.Leu22Pro | p.L22P | P22680 | protein_coding | deleterious(0.01) | benign(0.352) | TCGA-D7-8579-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracilum | CR | |
CYP7A1 | SNV | Missense_Mutation | c.803N>A | p.Ser268Tyr | p.S268Y | P22680 | protein_coding | deleterious(0.02) | benign(0.057) | TCGA-KB-A93H-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CYP7A1 | SNV | Missense_Mutation | novel | c.1207N>A | p.Asp403Asn | p.D403N | P22680 | protein_coding | tolerated(0.21) | benign(0.405) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
CYP7A1 | deletion | Frame_Shift_Del | novel | c.201delN | p.Phe67LeufsTer5 | p.F67Lfs*5 | P22680 | protein_coding | TCGA-D7-A6EY-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1581 | CYP7A1 | CYTOCHROME P450, DRUGGABLE GENOME, ENZYME | cholic acid | |||
1581 | CYP7A1 | CYTOCHROME P450, DRUGGABLE GENOME, ENZYME | atorvastatin | ATORVASTATIN | 16103896,15262185,26932749,21128988 |
Page: 1 |